查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数字 PCR 市场：到 2028 年的预测——按产品、技术、适应症、应用、最终用户和地区分析
市场调查报告书
商品编码
1218865

全球数字 PCR 市场：到 2028 年的预测——按产品、技术、适应症、应用、最终用户和地区分析

Digital PCR Market Forecasts to 2028 - Global Analysis By Product, Technology, Indication, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2022 年全球数字 PCR 市场规模将达到 5.3973 亿美元，预计到 2028 年将达到 21.4948 亿美元，预测期内復合年增长率为 25.9%。

数字聚合□链反应 (dPCR) 是一种用于定量核酸的新技术，它提供了一种灵敏且可重复的方法来估计样品中 DNA 或 RNA 的浓度。包括研究（基础和应用）、临床诊断和法医学在内的所有领域都对 dPCR 寄予厚望。dPCR 系统的应用包括拷贝数变异、稀有序列检测、突变检测、miRNA 分析、基因表达分析、下一代测序的样本量化等。

根据 GLOBOCAN 报告，2020 年全球约有 1929 万人被诊断出患有癌症。根据国际糖尿病联合会糖尿病地图集第 10 版 2021 年，全球约有 5.37 亿成年人被诊断患有糖尿病，到 2030 年和 2045 年这一数字将增加到 6.43 亿。预计到 2018 年将增长到 7.83 亿。

市场动态

促进者

越来越多地使用生物标誌物分析进行疾病诊断

在体液和组织中发现的核酸（DNA、microRNA、mRNA 等）是一类被称为生物标誌物和基因组标誌物的特征分子。通过表观遗传、遗传和蛋白质水平的分子谱分析，生物标誌物可以成为确定疾病性质和治疗效果的可靠和准确的信息来源。生物标誌物分析目前正用于诊断测试、疗效监测和药物开发。在生物标誌物分析中，使用 qPCR 和 dPCR 技术检测和测量分离样本中的遗传物质。在过去十年中，随着越来越多的公共机构和私营公司专注于监测疾病进展和开发个性化药物和治疗的新技术的研发，生物标誌物分析程序在临床上与疾病相关。它在诊断和预后方面越来越重要。

阻碍因素

系统成本高

虽然数字小工具有许多有用的应用程序，但它们也有可能阻止它们在市场上被广泛接受的缺点。与其他选择相比，数字小工具价格昂贵。这些元素在市场上的存在导致了多种选择。对于绝对定量，可以使用计数 PCR 代替数字聚合□链反应。基因表达、拷贝数变异和病毒载量均已量化。预计此类选项将抑制这些数字设备的市场扩张。

机会

dPCR 相对于实时聚合□的一些优势

数字聚合□链反应有助于提供目标核酸分子的全局测量，而不是从实时仪器获得的相对测量。这种绝对 DNA 量化带来的可重复性、灵敏度和精确度使研究人员能够更好地评估微小突变，甚至量化更小的差异。由于病毒中存在大量基因组类型，样本中模板浓度极低，实时仪器炼式反应儘管应用广泛，但已成功测试了多种寄生病原体，如疟疾和 COVID -19. 它不是检测传染病的首选技术。数字液滴技术可以克服这些问题并通过改进的组比较产生准确的结果。这些因素正在加速市场的扩张。

威胁

缺乏技术能力

常见的 dPCR 方法在 PCR 反应的指数阶段存在信号测量、需要优化和验证检测程序、由于反应抑製剂导致目标检测困难以及核甘酸模板质量差等问题。存在许多技术限制，例如无法检测分子。此外，致癌化学品的使用、试剂对 dsDNA 的化学附着以及无法测量 DNA 质量 (AluQuant) 是直接影响其在基因组研究中使用的 qPCR 试剂的操作限制。

COVID-19 的影响

由于 COVID-19 的影响，该市场在 2020 年显着增长。这是由于这种病毒的广泛流行，增加了对有效诊断以防止其传播的需求。在全球范围内，数字 PCR 市场发展迅猛。重新分配 COVID-19 治疗的医疗费用、增加对 COVID-19 诊断的需求，以及诊断中心和研究机构对该设备的使用增加，都推动了对该设备的需求。我是。全球高负担国家 COVID-19 检测的显着增加也促成了积极的结果。

基于芯片的数字 PCR 部分预计在预测期内将是最大的

基于芯片的数字 PCR 部分将看到有利可图的增长，因为基于芯片的数字 PCR 方法利用编织有数千个阀门和通道的硅芯片在纳升中执行大规模 rtPCR。估计。在检测次数相同的情况下，该芯片可以一次检测多达 48 或 96 个样本，让您从一次反应中获得更多洞察力。基于芯片的数字 PCR 因其降低交叉污染的风险和稳定的液滴流动而日益流行。未来，这种新技术很可能会诊断出更多的疾病。

预计诊断中心部分将在预测期内见证最高的复合年增长率

预计诊断中心部分将在预测期内呈现最快的复合年增长率。这些数字设备在各种类型的诊断中的广泛使用和传染病流行率的上升都是这一领域增长的原因。COVID-19 的爆发也促使许多市场进入者专注于创建和销售 COVID-19 诊断试剂盒。

占比最大的地区

由于其完善的医疗保健行业、投资新产品发布的顶级分子诊断公司的存在以及使用个性化药物的患者比例上升，北美将在预测期内占据最大的市场份额。预计将占据。北美数字 PCR 市场由于老年人口的增加、传染病的鑑定以及医疗设施的扩建而扩大。由于这些原因，该地区有望在预测期内实现盈利增长。

复合年增长率最高的地区

由于欧洲是製药製造和研究的主要参与者，预计在预测期内欧洲的复合年增长率最高。通过融合需要基因分析的技术，正在创建靶向治疗和个性化精准医疗等创新方法。由于欧洲为研究和开发提供了大量的机构资助，研究质量也在提高。由于该地区疾病的流行以及微阵列、PCR 和其他基因组学和蛋白质组学技术的使用，分子诊断学的使用正在增加。

重大发展

2022 年 4 月，Stira 和 Promega Corporation 宣布了一项联合营销协议，将样品製备与最新的 Maxwell 系统相结合，数字聚合□链反应与 6 色 Naica 系统相结合。该合作伙伴关係加强了两家公司的产品组合。

2022 年 3 月，Stilla 宣布与 EMEA 地区的 12 家分销商建立合作伙伴关係。通过这种合作关係，该公司扩大了其在欧洲、中东和非洲地区的业务。

2021 年 9 月，Thermo Fisher Scientific Inc. 宣布推出 Applied Biosystems Quant Studio Absolute Q 数字系统。

2020年6月，Stilla宣布推出全球首款6色数字聚合□链反应装置。

2020年5月，Stilla宣布推出数字聚合□链反应解决方案Naica System。该产品可以可靠地检测 SARS-CoV-2 病毒，并在参与 COVID-19 应对的所有实验室和医院测量其病毒载量。

本报告内容

  • 区域和国家细分市场份额评估
  • 给新进入者的战略建议
  • 涵盖 2020、2021、2022、2025 和 2028 年的市场数据
  • 涵盖市场趋势（市场驱动因素、驱动因素、机遇、威胁、挑战、投资机会、建议）
  • 基于市场估计的关键业务领域的战略建议
  • 竞争格局映射关键共同趋势
  • 公司概况，包括详细战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制服务

订阅此报告的客户将免费获得以下自定义选项之一。

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户要求对主要国家的市场估计、预测和復合年增长率（注：基于可行性检查。）
  • 竞争标桿
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

目录

第一章内容提要

第二章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 促进者
  • 抑製剂
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5 全球数字 PCR 市场，按产品

  • 乐器
  • 试剂和耗材
  • 软件和服务
  • 数字PCR设备
  • 其他产品

6. 全球数字 PCR 市场，按技术分类

  • 微滴式数字 PCR
  • 基于芯片的数字PCR
  • 光束数字 PCR
  • 其他技术

7. 全球数字 PCR 市场，按适应症分类

  • 肿瘤学
  • 感染
  • 遗传病
  • 其他适应症

8 全球数字 PCR 市场，按应用

  • 肿瘤检查
  • 血液筛查
  • 移植诊断
  • 调查
  • 其他应用

9. 全球数字 PCR 市场，按最终用户分类

  • 医院和诊所
  • 学术/研究机构
  • 诊断中心
  • 製药和生物技术行业
  • 法医研究所
  • 其他最终用户

10. 全球数字 PCR 市场，按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东

第十一章主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章公司简介

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • JN Medsys
  • QIAGEN
  • Stilla
  • Sysmex Corporation
  • Standard BioTools Inc.
  • Precigenome LLC.
  • Fluidigm Corp.
  • Formulatrix, Inc.
  • Avance Bioscience
  • Merck KGAA
  • Agilent Technologies, Inc.
  • BioMerieux
  • Takara Bio Inc.
  • Beckman Coulter, Inc.
  • General Electric
  • Roche Sequencing
  • PerkinElmer Inc.
  • Siemens
Product Code: SMRC22401

According to Stratistics MRC, the Global Digital PCR Market is accounted for $539.73 million in 2022 and is expected to reach $2149.48 million by 2028 growing at a CAGR of 25.9% during the forecast period. The digital polymerase chain reaction (dPCR) is a new technique for quantifying nucleic acids that provides a sensitive and reproducible means to estimate the concentration of DNA or RNA in a sample. Research (basic and applied), clinical diagnostics, forensics, and other sectors all show great promise for dPCR. Applications for dPCR systems include copy number variation, uncommon sequence detection, mutation detection, miRNA analysis, gene expression analysis, and next-generation sequencing sample quantification.

According to the GLOBOCAN report, in 2020, around 19.29 million people in the world are affected by cancer. According to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults all over the world were found to have diabetes; with the numbers projected to grow to 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Increasing use of biomarkers profiling for disease diagnostics

Nucleic acids (including DNA and micro RNA or mRNA), which may be found and measured in bodily fluids and tissues, are examples of distinctive molecules known as biomarkers or genomic markers. Through the process of molecular profiling at the epigenetic, genetic, and protein levels, a biomarker can be a dependable, precise source for determining the nature of a disease and therapeutic response. Currently, biomarker analysis is employed in diagnostic testing methods, therapeutic efficacy monitoring, and drug development. The isolated sample's genetic material is detected and measured using qPCR and dPCR technology in the biomarker analysis process. With more public and private organisations concentrating on R&D into novel techniques for monitoring disease progression and developing personalised medicines and treatment options, biomarker analysis procedures have grown in significance in the clinical diagnosis and prognosis of diseases over the past ten years.

Restraint:

High Cost of Systems

Digital gadgets have many useful applications, but they also have some drawbacks that may prevent widespread market acceptance. Its acceptance may be constrained by some issues, namely the higher price of these digital gadgets in comparison to alternative options. Multiple alternative possibilities are created as a result of this element in the market. For absolute quantification, counting PCR might be used instead of digital polymerase chain reaction. Gene expressions, copy number variation, and viral load are all quantified. This alternative is anticipated to restrain the market's expansion of these digital devices.

Opportunity:

Several Benefits of dPCR Over Real-time Polymerase

Digital polymerase chain reaction aids in delivering a comprehensive measure of the target nucleic acid molecules as opposed to the relative measure obtained from real-time instruments. Because of the reproducibility, sensitivity, and precision provided by this absolute DNA quantification, researchers are also able to properly assess minor mutations and quantify smaller differences. Due to the numerous types of genomes present in the virus and the extremely low template concentration present in the sample, real-time devices chain reaction is not a preferred technique for detecting various parasitic infectious diseases such as malaria and COVID-19, despite its widespread application. Digital droplet technologies get beyond these problems and produce precise results with improved group comparisons. These elements are therefore accelerating the market's expansion.

Threat:

Lack of technical skills

A typical dPCR method has a number of technical restrictions, including the measurement of the signal during the exponential phase of the PCR reaction, the requirement for assay procedure optimization and validation, difficulties in target detection caused by reaction inhibitors, and the inability to detect the target molecules due to the poor quality of the nucleotide template. Additionally, the usage of carcinogenic chemicals, chemical attachment of the reagent to dsDNA, and inability to measure DNA quality (AluQuant) are some of the operational constraints of qPCR reagents that have a direct impact on their use in genomic research.

COVID-19 Impact

The market grew significantly in 2020 as a result of COVID-19's effects. This is explained by the fact that the virus has spread widely, raising the need for efficient diagnostics to stop its transmission. The market for digital PCR in the world expanded tremendously. The demand for the devices was fuelled by the reallocation of healthcare funds for COVID-19 therapy, which led to an increase in the number of persons seeking a COVID-19 diagnosis and the use of the device in diagnostic centres and research facilities. The considerable growth of COVID-19 testing in high-burden nations worldwide also contributed to the favourable outcome.

The chip-based digital PCR segment is expected to be the largest during the forecast period

The chip-based digital PCR segment is estimated to have a lucrative growth, due to chip-based digital PCR method carries out rtPCR on a huge scale in nanoliter amounts by utilising silicon chips with thousands of interweaving valves and channels. With the same number of assays, the chip can test up to 48 or 96 samples at once, yielding numerous findings from a single response. Chip-based digital PCR is gaining popularity daily due to its decreased risk of cross-contamination and consistent droplet flow. In the future, additional diseases are probably going to be diagnosed with new technologies of this kind

The diagnostics centers segment is expected to have the highest CAGR during the forecast period

The diagnostics centers segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the expanding use of these digital devices for the diagnosis of various sorts of these diseases and the rising prevalence of infectious diseases are both responsible for the segment's growth. Additionally, numerous market participants boosted their focus on creating and marketing COVID-19 diagnostics kits as a result of the COVID-19 outbreak.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its well-established healthcare sector, the presence of top molecular diagnostics firms that invest in the release of new products, and the rise in the proportion of patients utilising personalised medicines. Because there were more elderly individuals, more infectious diseases were being identified, and there were improved healthcare facilities, the digital PCR market in North America expanded. With all of this, the region is anticipated to grow profitably during the projection period.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period; due to it is a major player in the creation and research of pharmaceuticals. Innovative approaches like targeted therapy and personalised precision medicine are being created by merging technology that requires genetic analysis. Because of the substantial institutional funding that Europe offers for R&D, the calibre of research has increased. Due to the high prevalence of diseases in the area and the use of microarray, PCR, and other genomic and proteomic techniques, there has been an increase in the use of molecular diagnostics.

Key players in the market

Some of the key players profiled in the Digital PCR Market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., JN Medsys, QIAGEN, Stilla, Sysmex Corporation, Standard BioTools Inc., Precigenome LLC., Fluidigm Corp., Formulatrix, Inc., Avance Bioscience, Merck KGAA, Agilent Technologies, Inc., BioMerieux, Takara Bio Inc., Beckman Coulter, Inc., General Electric, Roche Sequencing, PerkinElmer Inc. and Siemens

Key Developments:

In April 2022, Stilla and Promega Corporation announced their co-marketing agreement that combined sample preparation with the latest Maxwell systems and digital polymerase chain reaction on the six-color Naica system. This collaboration strengthened both companies' product portfolio.

In March 2022, Stilla announced its partnership with 12 distributors across the EMEA region. With this partnership, the company expanded its presence in the EMEA region.

In September 2021, Thermo Fisher Scientific Inc. announced the launch of Applied Biosystems Quant Studio Absolute Q a digital system.

In June 2020, Stilla announced the launch of the world's first six-color digital polymerase chain reaction instrument.

In May 2020, Stilla announced the availability of its digital polymerase chain reaction solution, the Naica system. The product can reliably detect the SARS-CoV-2 virus and measure its viral load in all research centers and hospitals involved in the fight against COVID-19.

Products Covered:

  • Instruments
  • Reagents & Consumables
  • Software and Services
  • Digital PCR Equipment
  • Other Products

Technologies Covered:

  • Droplet Digital PCR
  • Chip-based Digital PCR
  • Beaming Digital PCR
  • Other Technologies

Indications Covered:

  • Oncology
  • Infectious Diseases
  • Genetic Disorders
  • Other Indications

Applications Covered:

  • Oncology Testing
  • Blood Screening
  • Transplant Diagnostics
  • Research
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Academic & Research Organizations
  • Diagnostic Centers
  • Pharmaceutical & Biotechnology Industries
  • Forensic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital PCR Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Reagents & Consumables
  • 5.4 Software and Services
  • 5.5 Digital PCR Equipment
  • 5.6 Other Products

6 Global Digital PCR Market, By Technology

  • 6.1 Introduction
  • 6.2 Droplet Digital PCR
  • 6.3 Chip-based Digital PCR
  • 6.4 Beaming Digital PCR
  • 6.5 Other Technologies

7 Global Digital PCR Market, By Indication

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Genetic Disorders
  • 7.5 Other Indications

8 Global Digital PCR Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology Testing
  • 8.3 Blood Screening
  • 8.4 Transplant Diagnostics
  • 8.5 Research
  • 8.6 Other Applications

9 Global Digital PCR Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Academic & Research Organizations
  • 9.4 Diagnostic Centers
  • 9.5 Pharmaceutical & Biotechnology Industries
  • 9.6 Forensic Laboratories
  • 9.7 Other End Users

10 Global Digital PCR Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Bio-Rad Laboratories, Inc.
  • 12.3 JN Medsys
  • 12.4 QIAGEN
  • 12.5 Stilla
  • 12.6 Sysmex Corporation
  • 12.7 Standard BioTools Inc.
  • 12.8 Precigenome LLC.
  • 12.9 Fluidigm Corp.
  • 12.10 Formulatrix, Inc.
  • 12.11 Avance Bioscience
  • 12.12 Merck KGAA
  • 12.13 Agilent Technologies, Inc.
  • 12.14 BioMerieux
  • 12.15 Takara Bio Inc.
  • 12.16 Beckman Coulter, Inc.
  • 12.17 General Electric
  • 12.18 Roche Sequencing
  • 12.19 PerkinElmer Inc.
  • 12.20 Siemens

List of Tables

  • 1 Global Digital PCR Market Outlook, By Region (2020-2028) ($MN)
  • 2 Global Digital PCR Market Outlook, By Product (2020-2028) ($MN)
  • 3 Global Digital PCR Market Outlook, By Instruments (2020-2028) ($MN)
  • 4 Global Digital PCR Market Outlook, By Reagents & Consumables (2020-2028) ($MN)
  • 5 Global Digital PCR Market Outlook, By Software and Services (2020-2028) ($MN)
  • 6 Global Digital PCR Market Outlook, By Digital PCR Equipment (2020-2028) ($MN)
  • 7 Global Digital PCR Market Outlook, By Other Products (2020-2028) ($MN)
  • 8 Global Digital PCR Market Outlook, By Technology (2020-2028) ($MN)
  • 9 Global Digital PCR Market Outlook, By Droplet Digital PCR (2020-2028) ($MN)
  • 10 Global Digital PCR Market Outlook, By Chip-based Digital PCR (2020-2028) ($MN)
  • 11 Global Digital PCR Market Outlook, By Beaming Digital PCR (2020-2028) ($MN)
  • 12 Global Digital PCR Market Outlook, By Other Technologies (2020-2028) ($MN)
  • 13 Global Digital PCR Market Outlook, By Indication (2020-2028) ($MN)
  • 14 Global Digital PCR Market Outlook, By Oncology (2020-2028) ($MN)
  • 15 Global Digital PCR Market Outlook, By Infectious Diseases (2020-2028) ($MN)
  • 16 Global Digital PCR Market Outlook, By Genetic Disorders (2020-2028) ($MN)
  • 17 Global Digital PCR Market Outlook, By Other Indications (2020-2028) ($MN)
  • 18 Global Digital PCR Market Outlook, By Application (2020-2028) ($MN)
  • 19 Global Digital PCR Market Outlook, By Oncology Testing (2020-2028) ($MN)
  • 20 Global Digital PCR Market Outlook, By Blood Screening (2020-2028) ($MN)
  • 21 Global Digital PCR Market Outlook, By Transplant Diagnostics (2020-2028) ($MN)
  • 22 Global Digital PCR Market Outlook, By Research (2020-2028) ($MN)
  • 23 Global Digital PCR Market Outlook, By Other Applications (2020-2028) ($MN)
  • 24 Global Digital PCR Market Outlook, By End User (2020-2028) ($MN)
  • 25 Global Digital PCR Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
  • 26 Global Digital PCR Market Outlook, By Academic & Research Organizations (2020-2028) ($MN)
  • 27 Global Digital PCR Market Outlook, By Diagnostic Centers (2020-2028) ($MN)
  • 28 Global Digital PCR Market Outlook, By Pharmaceutical & Biotechnology Industries (2020-2028) ($MN)
  • 29 Global Digital PCR Market Outlook, By Forensic Laboratories (2020-2028) ($MN)
  • 30 Global Digital PCR Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.